Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Addition to Indices, and Stock Price Movements - Research Report on ACADIA Pharmaceuticals, InterMune, Tandem Diabetes Care,



  Addition to Indices, and Stock Price Movements - Research Report on ACADIA
  Pharmaceuticals, InterMune, Tandem Diabetes Care, Nektar Therapeutics and
                                  Greatbatch

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 25, 2013

NEW YORK, December 25, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting ACADIA
Pharmaceuticals, Inc. (NASDAQ: ACAD), InterMune Inc. (NASDAQ: ITMN), Tandem
Diabetes Care Inc (NASDAQ: TNDM), Nektar Therapeutics (NASDAQ: NKTR), and
Greatbatch, Inc. (NYSE: GB). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

ACADIA Pharmaceuticals, Inc. Research Report

On December 20, 2013, ACADIA Pharmaceuticals, Inc.'s (ACADIA Pharmaceuticals)
stock went up by 3.47% to close the day at $24.16. For the past three trading
days, the Company's stock went up by 5.04%, compared to the Dow Jones
Industrial Average which went up by 2.18% during the same three day trading
period. The Full Research Report on ACADIA Pharmaceuticals, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/3eb7_ACAD

--

InterMune Inc. Research Report

On December 20, 2013, InterMune Inc.'s (InterMune) stock advanced 4.97%. The
Company's stock went up by 4.81% during the past three trading days, compared
to the Nasdaq Composite which gained 2.01% during the same three day trading
period. The Full Research Report on InterMune Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/dd8c_ITMN

--

Tandem Diabetes Care Inc Research Report

On December 20, 2013, Tandem Diabetes Care Inc (Tandem) announced that the
Company was added to the Russell 2000® and Russell 3000® Indexes following
reconstitution of Russell Investment Group's family of US indexes, after the
market closing on December 20, 2013. Kim Blickenstaff, President and CEO of
Tandem, commented, "Being added to the Russell 2000 and Russell 3000 Indexes
creates an opportunity to increase our overall visibility among key
institutional investors. We believe that added exposure is ultimately
beneficial to the company, our shareholders, and our customers." The Full
Research Report on Tandem Diabetes Care Inc - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/a1d1_TNDM

--

Nektar Therapeutics Research Report

On December 20, 2013, Nektar Therapeutics' stock went up by 4.00%, closing at
$11.19. The Company's stock gained 3.23% during the past three trading days,
compared to the Dow Jones Industrial Average, which rose 2.18% during the same
trading period. The Full Research Report on Nektar Therapeutics - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/3421_NKTR

--

Greatbatch, Inc. Research Report

On December 20, 2013, Greatbatch, Inc.'s (Greatbatch) stock went up by 3.97%,
ending the day at $42.65. Greatbatch's stock rose 6.25% over the past three
trading days, compared to the Dow Jones Industrial Average, which gained 2.18%
during the same trading period. The Full Research Report on Greatbatch, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/87b5_GB

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement